Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘
Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision definitive (chemo)radiation.
PURPOSE To prospect ively assess diagnostic performance of response assessment fluorodeoxyglucose positron emission tomography/computed tomography ( FDG-PET/CT ) in patients with HNSCC treated with high-precision definitive (chemo)radiation . METHODS Fifty-seven patients treated on a prospect i ve clinical trial having post-treatment response assessment FDG-PET/CT scans were included . Clinico-pathologic findings and follow-up information was considered as reference st and ard . RESULTS First response assessment  FDG-PET/CT was done at a median of 9 weeks ( inter-quartile range 8 - 10 weeks ) from completion of treatment . The sensitivity , specificity , positive predictive value ( PPV ) , negative predictive value ( NPV ) , and accuracy of first response assessment FDG-PET/CT  for identifying residual disease at primary site was 50 % , 91.8 % , 50 % , 91.8 % , and 86 % . The corresponding figures for the neck were 62.5 % , 98 % , 83.3 % , 94.1 % , and 93 % . With a median follow-up of 26 months ( range 7 - 45 months ) , the 3-year loco-regional control ( 83.9 % vs 58.3 % , p=0.001 ) and overall survival ( 68.8 % vs 58.3 % , p=0.063 ) was significantly better in patients with negative response assessment scans . CONCLUSION The overall diagnostic accuracy of response assessment FDG-PET/CT is good , but its sensitivity and PPV is somewhat low , particularly for primary site . A negative response assessment FDG-PET/CT scan is highly suggestive of absence of viable disease that could be used to guide decision-making
Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘